Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679634 · ClinicalTrials.gov registry record · Phase 2
Retinoblastoma Phase II Expanded Access Clinical Trial
A Phase 2 study of Retinoblastoma, sponsored by Targeted Therapy Technologies.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06679634 is a Phase 2 study of Retinoblastoma that is actively recruiting participants, run by Targeted Therapy Technologies. The registered enrollment target is 30 participants, below the 591-participant average among 15 other Retinoblastoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06679634, a Phase 2 study of Retinoblastoma, is actively recruiting participants, sponsored by Targeted Therapy Technologies.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study investigators want to learn more about treatment of advanced or recurrent retinoblastoma. For children with retinoblastoma that have an advanced stage of presentation in one eye or if they have failed all conventional treatment, eye removal is considered. This study will investigate the utility of a chemoplaque(s) to salvage eyes involved with retinoblastoma. The goal of the study is to further determine/assess the safety and efficacy and optimal chemotherapy dose for retinoblastoma.
Conditions Studied
Interventions
- DRUG Chemoplaque also referred to as Episcleral Topotecan
Study Locations (1)
New York
- NewYork Presbyterian Morgan Stanley Children's Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06679634
The ClinicalTrials.gov registry entry for NCT06679634 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 591-participant average among 15 other Retinoblastoma trials with a reported enrollment target (95% lower). The listed sponsor is Targeted Therapy Technologies, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinoblastoma appearing as the primary indexed condition, and to 1 intervention - of which Chemoplaque also referred to as Episcleral Topotecan is the first listed.
NCT06679634 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06679634 about?
NCT06679634 is a clinical study titled "Retinoblastoma Phase II Expanded Access Clinical Trial". In this research study investigators want to learn more about treatment of advanced or recurrent retinoblastoma. For children with retinoblastoma that have an advanced stage of presentation in one eye or if they have failed all conventional treatment, eye removal is considered. This study will inves...
What is the current status of trial NCT06679634?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-02-21. Estimated completion is 2028-11.
What conditions does trial NCT06679634 study?
This clinical trial studies the following conditions: Retinoblastoma.
What interventions are being tested in trial NCT06679634?
The interventions under investigation include: Chemoplaque also referred to as Episcleral Topotecan (DRUG).
Who is sponsoring clinical trial NCT06679634?
This trial is sponsored by Targeted Therapy Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679634 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinoblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Chemotherapy in Treating Patients With Retinoblastoma
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma
COMPLETED · Phase 2
-
RB Liquid Biopsy Biorepository
RECRUITING
-
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.